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EPOCH trial care pathway; the 37 recommended processes of care 
 
Before surgery  
1. Consultant led decision making  
2. Computed tomography imaging within two hours of decision to perform test  
3. Early goal directed therapy for patients with severe sepsis/septic shock  
4. Analgesia within one hour of first medical assessment  
5. Antibiotic therapy within one hour of first medical assessment  
6. Correction of coagulopathy  
7. Maintain normothermia  
8. Active glucose management  
9. Documented mortality risk estimate  
10. Provided patient and relatives with oral and written information about treatment  
 
During surgery  
11. Surgery within six hours of decision to operate  
12. Consultant delivered surgery and anaesthesia  
13. WHO safe surgery checklist  
14. Early antibiotic therapy (unless inappropriate)  
15. Fluid therapy guided by cardiac output monitoring  
16. Low tidal volume protective ventilation  
17. Maintain normothermia  
18. Active glucose management  
19. Prescribe post-operative analgesia  
20. Prescribe post-operative nausea & vomiting prophylaxis  
21. Prescribe post-operative venous thromboembolism prophylaxis  
22. End of surgery risk evaluation  
23. Measure arterial blood gases and serum lactate  
24. Confirm full reversal of neuromuscular blockade  
25. Document core temperature  
26. Re-evaluate mortality risk estimate  
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After surgery  
27. Admission to critical care within six hours of surgery  
28. Analgesia: early review by acute pain team 
29. Continued antibiotic therapy where indicated with microbiology review  
30. Prophylaxis for post-operative nausea & vomiting  
31. Venous thromboembolism prophylaxis  
32. Maintain normothermia  
33. Active glucose management  
34. Daily haematology & biochemistry until mortality risk is low (senior opinion)  
35. Nutrition: early dietician review with consideration of benefits of enteral feeding  
36. Chest physiotherapy review on day one after surgery 
37. Critical Care Outreach review on standard ward with use of Early Warning Scores  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary figure 1. The EPOCH care pathway 
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Supplementary table 1. Number of hospitals included in each analysis. 
 
Hospitals (n=93) 
All-cause mortality within 90 days of surgery (primary)  93 (100) 
All-cause mortality within 180 days of surgery 93 (100) 
Duration of hospital stay (days) 91 (98) 
Hospital re-admission within 180 days of surgery 87 (94) 
 
 
 
 
Supplementary table 2. Summary statistics for duration of hospital stay and hospital re-
admission. 
 
Usual care 
Quality 
improvement 
Duration of hospital stay   
     Censored while in-hospital 29 (<1) 102 (1) 
     Discharged 7195 (86) 6250 (85) 
     Died in hospital 1096 (13) 1001 (14) 
Hospital re-admission within 180 days of surgery   
     No 4954 (62) 4331 (64) 
     Yes 1618 (20) 1242 (18) 
     Died without admission before 180 days 1397 (18) 1150 (17) 
 
 
 
 
Supplementary table 3. Summary effect of QI intervention over time 
 90-day mortality Hazard ratio (95% CI) 
p-value 
(overall) 
No QI 1393/8482 (16) Reference 0.15 
QI <5 weeks 198/1069 (19) 1.11 (0.94, 1.32) - 
QI 5-10 weeks 185/983 (19) 1.21 (1.01, 1.44) - 
QI >10 weeks 1025/6391 (16) 1.05 (0.90, 1.23) - 
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Supplementary figure 2. Mortality within 180 days. 
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Supplementary figure 3. Time to hospital re-admission. 
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1. INTRODUCTION 
Purpose of statistical analysis plan 
The purpose of this document is to provide details of the statistical analyses and presentation of results to be 
reported within the principal paper(s) of the EPOCH trial. Subsequent papers of a more exploratory nature will 
not be bound by this strategy but will be expected to follow the broad principles laid down within it.  Any 
exploratory, post-hoc or unplanned analyses will be clearly identified as such in the respective study analysis 
report. 
 
This document has been developed prior to examination of unblinded trial data. This plan is intended not to 
change or contradict the general aims of the protocol, but rather expand on them. In the event of a discrepancy 
the analyses described here will supersede those in earlier documents. 
 
Background 
EPOCH is a stepped wedge, cluster randomised trial which aims to evaluate the effect of a quality improvement 
intervention to promote the implementation of an integrated peri-operative care pathway in patients undergoing 
emergency laparotomy. The trial will take place in 90 hospitals, which have been grouped into 15 clusters based 
on geographical location (with approximately 6 hospitals per cluster). The trial will take place over an 85 week 
period, which has been divided into 17 time periods of 5 week each. All hospitals will start out receiving usual 
care during the first time period; during each subsequent time period, one cluster will switch over to the quality 
improvement intervention (the order the clusters switch has been randomised). By time period 16, all clusters 
will be receiving the quality improvement intervention.  
 
 
Inclusions/exclusion criteria 
Inclusion criteria  
• Included on the NELA database 
• Age 40 years and over 
• Undergoing non-elective surgery 
• Undergoing open abdominal surgery 
• Admitted to hospital during the 85 week trial period from March 3rd 2014, to Oct 19th, 2015 
 
Exclusion criteria  
• Patients who have previously been included in the EPOCH trial 
• Laparotomy to treat complications of recent elective surgery 
• Simple appendicectomy 
• Gynaecological laparotomy 
• Surgery related to organ transplant 
• Laparotomy for traumatic injury 
 
 
Changes from protocol 
• Defined the process measures to be summarised 
• Defined which baseline risk factors were to be adjusted for in the analysis 
• Clarified that hospitals which discontinue their emergency laparotomy service, or which merge with 
another hospital during the trial period will be excluded from the analysis at the point of 
discontinuation or merger 
• Clarified that the analysis will include a random-effect for the hospital-time period interaction. This is 
in accordance with new research indicating this analysis approach is required to preserve type I error 
rates at their nominal level 
• Clarified that hospital re-admission will be analysed using a competing-risk time-to-event model rather 
than a logistic regression model 
• Clarified that time to hospital discharge will be analysed using a competing-risk time-to event model 
rather than a simple time-to-event model 
 
Note that all changes from the protocol were made before any investigators had access to any trial data or to any 
results. 
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Changes from SAP version 1.0 
• Changed the covariates to be adjusted for in the analysis of clinical outcomes from age and gender, to 
age, gender, and indication for surgery.  
 
Note that all changes from version 1.0 of the SAP were made before any investigators had access to any clinical 
outcome data.  
 
 
Changes from SAP version 2.0 
• We had planned to calculate the primary outcome (mortality within 90 days of surgery) based on data 
obtained from government registries (i.e. Office for National Statistics in England, and similar agencies 
in Scotland and Wales), and analyse it as a binary endpoint using a logistic regression model. However, 
due to unforeseen issues, we were unable to obtain data from the Welsh registry (but did obtain data 
from the English and Scottish registries). This meant that under our original definition, all patients in 
Wales would be excluded from the analysis due to missing data, which could adversely affect results. 
In order to avoid excluding patients from Wales from the primary outcome analysis, we opted to 
change the analysis approach from a logistic regression model based on a binary endpoint to a survival 
analysis model based on a time-to-event endpoint; this allowed us to calculate time-to-mortality for 
patients in Wales based on in-hospital mortality data which is collected as part of NELA (with patients 
being censored at the time of hospital discharge). Time-to-mortality will still be calculated based on 
government registry data for patients in England and Scotland. We changed the secondary outcome 
‘mortality within 180 days’ in the same manner. The updated method for deriving these outcomes is 
available in Appendix 3. 
• One of the sensitivity analyses regarding missing data for the primary outcome was based upon a 
binary endpoint; this has been removed, as this approach does not work well for time-to-event 
outcomes.  
• Removed sensitivity analysis for primary outcome which included patients who presented to a hospital 
which merged with other hospitals after the date of the merge, as this affected very few patients. 
• Added specification that missing data in the baseline covariates that will be adjusted for in the analysis 
will be handled using mean imputation (for continuous variables) and a missing indicator variable (for 
categorical variables).  
• Appendix 5: Updated to reflect new data fields in NELA, and a ‘multiple indications’ category was 
added as the categories are not mutually exclusive. 
• Clarified that the additional analysis assessing the intervention in patients aged <40, or who underwent 
laparoscopic surgery would not be a formal analysis, but would only present summary statistics. This is 
because we expect few patients and outcome events in this group, and our specified statistical models 
(with three levels of random-effects) would likely not work well.  
• Appendix 2: clarified that patients who presented to a hospital that merged with other hospitals after 
the date of the merge would be excluded from the analysis (this was stated in v2.0 of the SAP, but 
inadvertently left out from the appendix) 
 
 
Changes from version 2.0 of the SAP were after the trial statistician (BK) had access to data, but before 
statistical analysis began (i.e. during the data cleaning stage), and before any other investigators had access to 
the data.   
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2. OUTCOME MEASURES 
 
Primary outcome 
• All-cause mortality within 90 days following surgery 
 
Secondary outcomes 
• All-cause mortality within 180 days following surgery 
• Duration of hospital stay (defined as the number of days from surgery until hospital discharge) 
• Hospital re-admission within 180 days of surgery 
 
The start of surgery will be defined as when the patient enters the operating theatre or anaesthetic room.  
 
Process measures 
1. Consultant led decision to operate 
2. When consultant led decision to operate, did this consultant personally review patient at time of 
decision? 
3. Preoperative documentation of risk  
4. Time from decision made to operate to entry into operating theatre 
5. Patient entered operating theatre within time-frame specified based on their urgency level (i.e. <2 
hours, 2-6 hours, 6-18 hours, or >18 hours) 
6. Consultant surgeon present in operating theatre 
7. Consultant anaesthetist present in operating theatre 
8. Goal directed fluid therapy used during surgery 
9. Arterial lactate measured at end of surgery  
10. Critical care admission immediately after surgery 
 
 
 
3. STUDY METHODS 
Overall study design and plan 
Multi-centre, stepped wedge cluster randomised trial conducted in 90 NHS hospitals over an 85 week period, 
divided into 17 time period of 5 weeks. Hospitals will be grouped into fifteen clusters of six on a geographical 
basis. The quality improvement intervention will commence in one geographical area each five week step from 
the 2nd to the 16th time period, with the order of geographical areas determined by computer based 
randomisation.  
 
Randomisation 
Simple randomisation was used to randomise one geographical area of hospitals to receive the intervention in 
each of the fifteen time periods 2 to 16. Randomisation was performed by an independent statistician. Local 
investigators were notified 12 weeks in advance of activation of the quality improvement project at their hospital. 
 
Sample size  
Prospectively collected data from the recently published Emergency Laparotomy Network study in 35 NHS 
hospitals closely match our inclusion/exclusion criteria and describe a median of 184 eligible patients aged ≥40 
years per hospital per year (range 32-736). Data from the Hospital Episodes Statistics database for the year ending 
April 2011 gives average 90-day mortality as 25%. These data have been used to estimate the baseline mortality 
rate and between hospital coefficient of variation. Power calculations are based on the methodology proposed by 
Hussey & Hughes, for an analysis with fixed time effects and random cluster effects, modified to exclude data 
collected during the five week period in which the intervention commences in individual hospitals. The trial will 
be conducted in at least 90 NHS hospitals over a period of 85 weeks during which time we expect to receive data 
describing 27,540 patients undergoing emergency laparotomy. For a baseline 90-day mortality of 25%, between 
hospital coefficient of variation of 0.15, constant case-load (18 patients per 5 weeks per hospital) and assuming 
independent hospital effects, the study would achieve 92% power to detect a 12% relative risk reduction in 
mortality from 25% to 22% (two-sided p<0.05). This calculation is insensitive to the coefficient of variation but 
sensitive to the effect size. In practice, power may be reduced by correlation between hospitals within geographic 
areas and by variation in case-load between hospitals. The worst case scenario is one where each of the 15 
geographic areas functions effectively as a single large hospital, reducing the power to 83%. This figure 
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incorporates an adjustment for variable case-load from the pilot data. Thus the power of the study to detect a 12% 
relative risk reduction lies between 83% and 92%.  
 
 
 
4. DATA COLLECTION 
 
Data to be collected at different stages: 
 
Pre-operative data: Age, Sex, American Society of Anesthesiologists (ASA) Score, Co-morbid disease, Date of 
hospital admission, Admitting specialty, Time and date of decision to perform surgery, Time to diagnostic 
imaging (usually computed tomography scan of the abdomen), Documented mortality risk before surgery (Y/N).  
 
Intra-operative data: Urgency of surgery, Duration, time and date of surgery, Grades of most senior surgeon and 
anaesthetist present in theatre, Surgical procedure performed, Underlying pathology. 
 
180-day follow-up: Critical care admission, Duration of hospital stay, Hospital readmission and mortality.  
 
 
 
5. ANALYSIS PRINCIPLES 
Patients and hospitals to be included in the analysis 
All analyses will be conducted on an intention-to-treat basis. All eligible patients with available outcome data 
who attended a participating hospital during the 85-week trial period will be included in the analysis. Patients who 
presented to hospital during the 5-week time period immediately after the quality improvement implementation 
will be excluded from the analysis, in order to allow time for the intervention to take effect.  
 
Hospitals that underwent randomisation but subsequently withdrew prior to the trial start date (March 3rd, 2014) 
will be excluded from the analysis. Hospitals that withdraw from the trial during the trial period or do not 
implement the intervention will be included in the analysis. Hospitals that discontinue their emergency laparotomy 
service during the trial period will be included in the analysis up until the point of discontinuation, and excluded 
after this point. Hospitals that merge with another hospital(s) during the trial period will be included in the analysis 
up until the point of the merger, and excluded after this point. Hospitals that withdraw from data collection during 
the trial period will be included in the analysis up until the point of the withdrawal, and excluded after this point. 
Patients will be considered exposed to the intervention based on the randomisation schedule, regardless of whether 
the intervention was actually implemented.  
 
Justification for excluding hospitals who merge with other hospitals during the trial period 
When hospitals merge they can be seen to form a ‘new’ hospital. The types of patients who present to the new 
hospital may be different to those that presented to the ‘original’ hospital (e.g. due to a wider or different catchment 
area). There may be differences in staff between the new and original hospitals (e.g. differences in doctors, 
surgeons, nurses, etc). In some cases there may be differences in available equipment. This could all lead to 
substantial differences between the pre- and post-merger outcomes for patients. Because the stepped-wedge trial 
relies heavily on a within-hospital comparison, differences between pre- and post-merger outcomes could 
substantially skew this comparison, which could lead to bias in the estimated treatment effect.  
 
General analysis principles 
For analysis of the primary and secondary outcomes, the following summaries will be provided: 
• The number of patients included in the analysis, by treatment group   
• The number of hospitals included in the analysis 
• A summary statistic for the outcome (e.g. the number (%) of patients experiencing an event for 
binary outcomes) 
• The estimated treatment effect with its 95% confidence interval and a two-sided p-value  
 
The significance level is set at 5%. All analyses will include time-period in the model as a fixed-effect using 
indicator variables. All analyses will adjust for age, gender, and indication for surgery (peritonitis, perforation, 
abdominal infection, intestinal obstruction, haemorrhage, ischaemia, other, or multiple indications) using fixed 
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factors. Age will be included as a continuous covariate, and will be assumed to have a linear association with 
the outcome. Missing baseline data will be imputed using mean imputation for continuous variables (age), and 
using a missing indicator for categorical variables (gender, indication for surgery) (based on guidance from 
White IR, Thompsons SG. Adjusting for partially missing baseline measurements in randomized trials. Stat 
Med 2005). 
 
Primary outcome 
The primary outcome (all-cause mortality up to 90 days following surgery) will be analysed using a mixed-
effects parametric survival model, with a Weibull survival distribution. This model will include random-
intercepts for geographical area, hospital, and the interaction between hospital and time-period. Time-period 
will be included in the model as a fixed-effect using indicator variables. Age, gender, and indication for surgery 
will also be included in the model as fixed factors.  
 
Note that we are including the interaction between hospital and time-period as a random-effect as recent 
research has indicated this is required in order to preserve type I error rates at the nominal level (i.e. Morgan K, 
Forbes A, Keogh R, Jairath V, Kahan B. Choosing appropriate analysis methods for cluster randomised cross-
over trials with a binary outcome. Accepted.) 
An example dummy dataset is provided in table 1 and example Stata code is provided below to demonstrate 
how this analysis will be implemented. 
 
Example Stata code 
stset time_to_outcome, failure(outcome)  
 
mestreg treatment i.time_period age gender i.indication_surgery || geo_area: || hospital: || 
hospital_time_period: , distribution(weibull) 
 
 
If there are convergence issues with this analysis approach, we will use the strategy shown in table 2 to find an 
analysis approach which converges.  
 
 
Table 1 – Example dataset 
Geographical 
area  
Hospital  Time period  Hospital*time 
period interaction 
Treatment Patient 
1 1 1 1 0 1 
1 1 1 1 0 2 
1 1 2 2 0 3 
1 1 2 2 0 4 
1 2 1 3 0 5 
1 2 1 3 0 6 
1 2 2 4 0 7 
1 2 2 4 0 8 
2 3 1 5 0 9 
2 3 1 5 0 10 
2 3 2 6 1 11 
2 3 2 6 1 12 
2 4 1 7 0 13 
2 4 1 7 0 14 
2 4 2 8 1 15 
2 4 2 8 1 16 
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Table 2 – Analysis approaches to be used if the primary method of analysis fails to reach convergence 
 Change from previous strategy Example Stata code 
1 Remove the random-effect for the 
hospital/time-period interaction 
mestreg outcome treatment i.time_period age gender 
i.indication_surgery || geo_area: || hospital: , distribution(weibull) 
 
2 Remove the random-effect for hospital mestreg outcome treatment i.time_period age gender 
i.indication_surgery || geo_area: , distribution(weibull) 
 
3 Adjust for the fixed-effect of time as a 
continuous covariate using restricted cubic 
splines with 7 knot points (where 
rcs_time_period* are the variables forming 
the restricted cubic spline) 
mestreg outcome treatment rcs_time_period* age gender 
i.indication_surgery || geo_area: , distribution(weibull) 
 
 
 
 
Secondary outcomes 
All-cause mortality up to 180 days 
All-cause mortality up to 180 days following surgery and hospital re-admission within 180 days of surgery will 
be analysed using the same approach as the primary outcome.  
 
Duration of hospital stay 
Duration of hospital stay will be analysed using a competing-risk time-to-event model, which recognises 
mortality as a competing risk for hospital discharge. Because there are no facilities for analysing competing risk 
data using mixed-effects models in Stata, we will use robust standard errors which account for clustering by 
geographical area. This analysis will be implemented in Stata as follows: 
 
stset cc_time_to_discharge, failure(cc_discharge == 1)   
stcrreg treatment i.time_period age gender i.indication_surgery, compete(cc_discharge == 2) vce(cluster 
geo_area) 
 
Where: 
cc_discharge is a variable indicating whether the patient was discharged home (=1), died in hospital (=2), or 
was censored (=0), and cc_time_to_discharge is a variable indicating the time to the event.  
 
Hospital re-admission within 180 days 
This outcome will be analysed using a competing-risk time-to-event model, which recognizes mortality as a 
competing risk for hospital re-admission. It will be implemented using the same code as duration of hospital 
stay above.   
 
 
Secondary analyses of the primary outcome  
Evaluating the effect of the intervention over time 
We will perform a secondary analysis of the primary outcome to evaluate the effect of the intervention over time 
(i.e. whether the intervention effect improves over time). This analysis will include patients who presented to 
hospital during the 5-week period immediately after implementation of the quality improvement intervention. 
We will evaluate the following four groups: 
 
• Usual care; 
• The quality improvement (QI) intervention implemented for less than 5 weeks 
• The QI intervention was implemented for 5 weeks or more and less than 10 weeks 
• The QI intervention was implemented for 10 weeks or more 
 
This analysis will allow us to determine whether the effectiveness of the QI intervention improves over time. 
The analysis will be implemented using the same method as for the primary analysis of the primary outcome.  
 
 
24 
 
 
 
Inclusion of other patient populations which may be affected by the intervention 
We will perform a sensitivity analysis to assess whether results are generalisable to other patient populations 
which may have been affected by the intervention. This includes patients who underwent laparoscopic surgery, 
and patients who are aged 18-40 years.  
 
Due to the small number of patients in these groups, we will summarise results descriptively, rather than 
undertaking a formal statistical analysis. We will summarise the number (%) of patients in the treatment arms 
who experience a primary outcome event. The denominator for this analysis will include patients who either 
underwent laparoscopic surgery or were aged 18-40 years (or both), and who met all other eligibility criteria.   
 
Process measures 
The process measures will be summarized according to treatment group. For example, for binary process 
measures (e.g. ‘Goal directed fluid therapy used during surgery’), the number (%) of patients for whom the 
measure was met will be summarised separately for patients presenting during the usual care period and patients 
presenting during the intervention period.  
 
Because the trial intervention is complex, and we will not be able to distinguish the effects of a change in any 
one process measure on patient outcomes, no formal statistical analysis will be performed. This is to avoid any 
misinterpretation that changes in some process measures affected patient outcomes whilst others did not.  
 
Graphs and other data summaries 
Survival curves for mortality up to 180 days from surgery 
We will present two graphs which display the survival curves for mortality up to 180 days after surgery. 
Survival curves will be presented for each treatment arm. The first graph will be a Kaplan-Meier plot. It should 
be noted that this plot is affected by overall time trends in the outcome (e.g. if mortality rates improved over 
time, regardless of the intervention).  
 
Therefore, the second graph will show the estimated survival curve based on a mixed-effects time-to-event 
model, which corrects for time trends. The Stata code to implement this graph is: 
 
 stset time_to_death, failure(died_180days) 
mestreg treatment i.time_period age gender i.indication_surgery || geo_area: || hospital: || 
hospital_time_period: , distribution(Weibull)  
 
stcurve, surv at1(treatment=0) at2(treatment=1) 
 
Other data summaries 
• The number of patients who are excluded from each analysis (and the reasons why) will be 
summarized.  
• The number of cluster activation meetings that occurred within ±2 weeks of the date based on the 
randomisation list 
• The number of hospitals sending at least one person to the first QI activation meeting 
• The number of hospitals sending at least one of their named QI leads to the first QI activation meeting 
• The number of hospitals sending at least one person to the second QI activation meeting 
• The number of hospitals sending at least one of their named QI leads to the second QI activation 
meeting  
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Dummy tables 
 
Table 1 – Patient characteristics 
 Missing data Summary measure 
 Intervention 
– no. (%) 
Control – 
no. (%) 
Intervention 
(n=…) 
Control 
(n=…) 
Baseline characteristics     
Female – no. (%)     
Age – mean (SD)     
Indication for surgery – no. (%)     
     Peritonitis     
     Perforation     
     Abdominal infection     
     Intestinal obstruction     
     Haemorrhage     
     Ischaemia     
     Other     
Pre-operative characteristics     
Estimated risk of death – no. (%)     
     Low (<5%)     
     Medium (5-10%)     
     High (>10%)     
     Not documented     
ASA score – no. (%)     
     1 (no systemic disease)     
     2 (mild systemic disease)     
     3 (severe systemic disease, not life 
threatening) 
    
     4 (severe, life threatening)     
     5 (moribund patient)     
P-POSSUM score – mean (SD)     
Blood lactate (mmol/l) – mean (SD)     
Systolic blood pressure (mmHg) – mean 
(SD) 
    
Glasgow coma scale – mean (SD)     
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Table 2 – Main results for primary and secondary outcomes 
 
 Missing data 
(intervention) 
Missing data 
(control) 
Summary 
measure 
(intervention) 
Summary 
measure 
(control) 
Treatment 
effect (95% 
CI) 
P-value 
All-cause mortality up 
to 90 days from 
surgery (primary 
outcome) 
      
All-cause mortality up 
to 180 days from 
surgery 
      
Hospital re-admission 
within 180 days of 
surgery 
      
Duration of hospital 
stay 
      
 
 
 
Table 3 – Process measures 
 
 Missing data 
(intervention) 
Missing data 
(control) 
Summary 
measure 
(intervention) 
Summary 
measure 
(control) 
Consultant led decision to operate     
When consultant led decision to 
operate, did this consultant personally 
review patient at time of decision? 
    
Preoperative documentation of risk      
Time from decision made to operate to 
entry into operating theatre 
    
Patient entered operating theatre within 
time-frame specified based on their 
urgency level (i.e. <2 hours, 2-6 hours, 
6-18 hours, or >18 hours) 
    
Consultant surgeon present in 
operating theatre 
    
Consultant anaesthetist present in 
operating theatre 
    
Goal directed fluid therapy used during 
surgery 
    
Arterial lactate measured at end of 
surgery  
    
Critical care admission immediately 
after surgery 
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Determining eligibility criteria in NELA dataset 
 
Inclusions/exclusion criteria 
Inclusion criteria  
• Included on the NELA database 
• Age 40 years and over 
• Undergoing non-elective surgery 
• Undergoing open abdominal surgery 
• Admitted to hospital during the 85 week trial period from March 3rd 2014, to Oct 19th, 2015 
 
Exclusion criteria  
• Data previously included in the EPOCH trial 
• Laparotomy to treat complications of recent elective surgery 
• Simple appendicectomy 
• Gynaecological laparotomy 
• Surgery related to organ transplant 
• Laparotomy for traumatic injury 
 
 
Identifying eligible patients from the NELA dataset 
 
Inclusion criteria NELA field 
ID 
NELA Data item Possible values Patient included if NELA 
data item: 
Age 40 years and 
over 
1.4 Age on arrival Any age ≥40 
Undergoing non-
elective surgery 
   Elective surgery cases not 
collected by NELA 
Undergoing open 
abdominal surgery 
5.4 Procedure 
approach 
-Open 
-Laparoscopic 
-Laparoscopic 
converted to open 
-Laparoscopic assisted 
Open, Laparoscopic 
converted to open, or 
Laparoscopic assisted 
Admitted within 85 
week period from 
March 3rd, 2014 to 
Oct 19th, 2015 
1.9 Date and time 
patient admitted 
to this hospital 
Any date From March 3rd 2014 to 
Oct 19th, 2015 (inclusive) 
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Identifying ineligible patients from the NELA dataset 
 
Exclusion criteria NELA field ID NELA Data item Possible values Patient excluded if NELA 
data item: 
Laparotomy to treat 
complications of recent 
elective surgery 
5.1 Type for 
procedure 
-First surgical 
procedure after 
admission 
-Surgery for 
complication of 
previous surgical 
procedure within same 
admission 
Surgery for complication of 
previous surgical procedure 
within same admission 
 5.2 Indication for 
surgery 
-Planned relook 
-Peritonitis 
-Perforation 
-Abdominal abscess 
-Anastomotic leak 
-Intestinal fistula 
-Sepsis (other) 
-Intestinal obstruction 
-Haemorrhage 
-Ischaemia 
-Colitis 
-Abdominal wound 
dehiscence 
-Abdominal 
compartment 
syndrome 
-Other 
Planned relook 
Simple appendicectomy    Not collected by NELA 
Gynaecological laparotomy    Not collected by NELA 
Surgery related to organ 
transplant 
   Not collected by NELA 
Laparotomy for traumatic 
injury 
   Not collected by NELA 
 
Patients included in the main analyses for the primary, secondary, and process measure outcomes 
The following algorithm will be used to determine which patients will be included in the main analysis for each 
outcome. Briefly, eligible patients who are recorded on the NELA database, who have not presented to hospital 
in the 5 week period immediately after implementation of the intervention, and who have available outcome 
data will be included in the analysis.  
 
Algorithm: 
Patients will be included if: 
 
• 1.4 ≥ 40; and 
• 5.4 = Open, Laparoscopic converted to open, or Laparoscopic assisted; and 
• 1.9 is between March 3rd 2014 and October 19th 2015 (inclusive); and 
• 1.9 is not between the date of implementation (based on the randomisation list) and 35 days after the 
implementation date; and 
• 5.1 ≠ Surgery for complication of previous surgical procedure within same admission; and 
• 5.2 ≠ Planned relook; and 
• Patient has not presented to a hospital that has merged with other hospitals after the date of the merge; 
and 
• Outcome variable is not missing 
 
If any of the above data fields for the eligibility criteria are missing, the patient will be excluded from analysis.  
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Evaluating the effect of the intervention over time 
This analysis will include the same set of patients as in the primary analyses above, but will additionally include 
patients who presented during the 5-week period immediately after implementation, i.e. the algorithm will be 
the same as above, except the criteria “1.9 is not between the date of implementation (based on the 
randomisation list) and 35 days after the implementation date” will be removed. 
 
 
Inclusion of other patient populations which may be affected by the intervention 
Patients will be included if: 
 
• 1.4 < 40 or 5.4 = Laparoscopic; and 
• 1.9 is between March 3rd 2014 and October 19th 2015 (inclusive); and 
• 1.9 is not between the date of implementation (based on the randomisation list) and 35 days after the 
implementation date; and 
• 5.1 ≠ Surgery for complication of previous surgical procedure within same admission; and 
• 5.2 ≠ Planned relook; and 
• Outcome variable is not missing 
 
Analysis plan appendix 3: Calculating primary and secondary outcomes  
All primary and secondary outcomes will be measured from the date of surgery. The date of surgery is based on 
question 4.1 in the NELA dataset “Date and time of entry in to operating theatre/anaesthetic room (not theatre 
suite)”.  
 
 
 
 
Outcome Calculation 
All-cause mortality within 90 days 
following surgery 
This outcome will be defined by two variables: death (yes/no), and the time to death. 
 
For patients in England and Scotland (using government registry death data): 
 
Death: 
 
-‘Yes’ if the patient died, and the difference between their date of death and 4.1 is less 
than or equal to 90 
 
-‘No’ if the patient died, but the difference between their date of death and 4.1 is 
greater than 90 
 
-‘No’ if the patient did not die 
 
-Missing if the patient died, but their date of death is not available, or if it is unknown 
whether the patient died, if 4.1 is missing, or if the date of death is before 4.1 and this 
discrepancy cannot be resolved 
 
Time to death: 
-If ‘death’=’yes’, then time to death is calculated as the difference between their date 
of death and 4.1. If this is 0 (i.e. the patient died on the day of surgery), this will be set 
to 0.5 days; this is so the patient can be included in the analysis (as Stata excludes 
outcomes with an event time of 0) 
 
-if ‘death’=’no’, this is set to 90 days 
 
For patients in Wales: 
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-‘Yes’ if 7.7 = “Dead”; and the difference between their date of death (in 7.8) and 4.1 
is less than or equal to 90 
 
-‘No’ if the patient died, but the difference between their date of death and 4.1 is 
greater than 90 
 
-‘No’ if the patient was discharged or still in hospital at day 60 (as patients who are 
still in hospital at day 60 are sometimes censored at that point in the NELA dataset) 
 
-Missing if the patient died, but their date of death is not available, or if it is unknown 
whether the patient died, if 4.1 is missing, or if the date of death is before 4.1 and this 
discrepancy cannot be resolved 
 
Time to death: 
-If ‘death’=’yes’, then time to death is calculated as the difference between their date 
of death and 4.1. If this is 0 (i.e. the patient died on the day of surgery), this will be set 
to 0.5 days; this is so the patient can be included in the analysis (as Stata excludes 
outcomes with an event time of 0) 
 
-if ‘death’=’no’ (i.e. the patient was discharged or the patient is still in hospital at day 
60), this is the date of discharge or 90 days (whichever is sooner), or 60 days if they are 
still in hospital then 
 
All-cause mortality within 180 days 
following surgery 
This outcome will be defined by two variables: death (yes/no), and the time to death. 
 
For patients in England and Scotland (using government registry death data): 
 
Death: 
 
-‘Yes’ if the patient died, and the difference between their date of death and 4.1 is less 
than or equal to 180 
 
-‘No’ if the patient died, but the difference between their date of death and 4.1 is 
greater than 180 
 
-‘No’ if the patient did not die 
 
-Missing if the patient died, but their date of death is not available, or if it is unknown 
whether the patient died, if 4.1 is missing, or if the date of death is before 4.1 and this 
discrepancy cannot be resolved 
 
Time to death: 
-If ‘death’=’yes’, then time to death is calculated as the difference between their date 
of death and 4.1. If this is 0 (i.e. the patient died on the day of surgery), this will be set 
to 0.5 days; this is so the patient can be included in the analysis (as Stata excludes 
outcomes with an event time of 0) 
 
-if ‘death’=’no’, this is set to 180 days 
 
For patients in Wales: 
 
-‘Yes’ if 7.7 = “Dead”; and the difference between their date of death (in 7.8) and 4.1 
is less than or equal to 180 
 
-‘No’ if the patient died, but the difference between their date of death and 4.1 is 
greater than 180 
 
-‘No’ if the patient was discharged or still in hospital at day 60 
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-Missing if the patient died, but their date of death is not available, or if it is unknown 
whether the patient died, if 4.1 is missing, or if the date of death is before 4.1 and this 
discrepancy cannot be resolved 
 
Time to death: 
-If ‘death’=’yes’, then time to death is calculated as the difference between their date 
of death and 4.1. If this is 0 (i.e. the patient died on the day of surgery), this will be set 
to 0.5 days; this is so the patient can be included in the analysis (as Stata excludes 
outcomes with an event time of 0) 
 
-if ‘death’=’no’ (i.e. the patient was discharged or the patient is still in hospital at day 
60), this is the date of discharge or 180 days (whichever is sooner), or 60 days if they 
are still in hospital then 
 
Duration of hospital stay (defined as 
the number of days from surgery until 
hospital discharge) 
This outcome will be defined by two variables: the discharge event (discharged/died 
before discharge/censored), and time to the discharge event. 
 
-Discharge event = ‘Discharged’ if 7.7 = “Alive”; time to discharge event is calculated 
as difference as the difference in dates between 7.8 and 4.1 
 
--Discharge event = ‘Died before discharge’ if 7.7 = “Dead”; time to discharge is 
calculated as difference as the difference between the date of death and 4.1 
 
-Discharge event = ‘Censored’ if 7.7 = “Still in hospital at 60 days”; time to discharge 
is 60 days 
 
-Missing if 7.7 = “Alive” and 7.8 is missing or 4.1 is missing, or if 7.7 = “Dead” and a 
date of death is not available or 4.1 is missing  
 
Hospital re-admission within 180 days 
of surgery 
This outcome will be defined by two variables: the re-admission event (re-
admitted/died before re-admission/not re-admitted), and time to the re-admission event. 
 
-Re-admission event = ‘Yes’ if the patient was re-admitted to hospital within 180 days; 
time to re-admission event is calculated as the difference between the date of their first 
re-admission and 4.1  
 
-Re-admission event = ‘Died before re-admission’ if the patient died within 180 days 
and was not re-admitted to hospital; time to re-admission event is calculated as 
difference as the difference between the date of death and 4.1 
 
-Re-admission event = ‘Censored’ if the patient was alive up to 180 days and not re-
admitted to hospital; time to re-admission event is 180  
 
-Missing if the patient was re-admitted but their date of re-admission is not available or 
4.1 is missing, or if it is unknown whether the patient was re-admitted, or if 7.7 = 
“Dead” and a date of death is not available or if 4.1 is missing 
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Calculating process measures  
1. Consultant led decision to operate 
2. When consultant led decision to operate, did this consultant personally review patient at time of 
decision? 
3. Preoperative documentation of risk  
4. Time from decision made to operate to entry into operating theatre 
5. Patient entered operating theatre within time-frame specified based on their urgency level (i.e. <2 
hours, 2-6 hours, 6-18 hours, or >18 hours) 
6. Consultant surgeon present in operating theatre 
7. Consultant anaesthetist present in operating theatre 
8. Goal directed fluid therapy used during surgery 
9. Arterial lactate measured at end of surgery  
10. Critical care admission immediately after surgery 
 
 
 
Process measure Calculation 
1. Consultant led decision to operate -‘Yes’ if 2.4 = “Consultant” 
 
-‘No’ if 2.4 is anything other than “Consultant” 
 
-Missing if 2.4 is missing 
2. When consultant led decision to operate, did this consultant 
personally review patient at time of decision? 
-‘Yes’ if 2.5 = “Yes” 
 
-‘No’ if 2.5 = “No” 
 
-Missing if 2.5 = “Unknown” 
 
*Note: patients for whom 2.4 is not “Consultant” are 
excluded.  
3. Preoperative documentation of risk  -‘Yes’ if 3.1 = “low (<5%)” or “medium (5-10%)” or “high 
(>10%)” 
 
-‘No’ if 3.1 = “Not documented” 
 
-Missing if 3.1 is missing 
4. Time from decision made to operate to entry into operating 
theatre 
-calculated as the difference between date/time in 4.1 and 
the date/time in 2.2 
 
-missing if either 2.2 or 4.1 are missing/not known  
5. Patient entered operating theatre within time-frame specified 
based on their urgency level (i.e. <2 hours, 2-6 hours, 6-18 hours, 
or >18 hours) 
-‘Yes’ if (4) is less than or equal to time specified in 3.22 
 
-‘No’ if (4) is more than time specified in 3.22 
 
Missing if (4) or 3.22 is missing 
6. Consultant surgeon present in operating theatre -‘Yes’ if 4.2 = “Consultant”  
 
-‘No’ if 4.2 is anything other than “Consultant” 
 
-Missing if 4.2 is missing 
7. Consultant anaesthetist present in operating theatre -‘Yes’ if 4.3 = “Consultant”  
 
-‘No’ if 4.3 is anything other than “Consultant” 
 
-Missing if 4.3 is missing 
8. Goal directed fluid therapy used during surgery -‘Yes’ if 4.4 = “Cardiac output monitor” or “Other”  
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-‘No’ if 4.4 = “Not provided” 
 
-Missing if 4.4 is missing 
9. Arterial lactate measured at end of surgery -‘Yes’ if 6.3 = any number   
 
-‘No’ if 6.3 = “Not performed” 
 
-Missing if 6.3 is missing 
10. Critical care admission immediately after surgery -‘Yes’ if 6.24 = “Level 2 HDU” or “Level 3 ICU”  
 
-‘No’ if 6.24 = “Ward” 
 
-Missing if 6.24 is missing 
 
*Note: patients for whom 6.24 = “Died prior to discharge 
from theatre complex” will be excluded from the 
denominator 
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Calculating indication for surgery  
The variable ‘indication for surgery’ (which will be included in the regression models for the clinical outcomes) 
will be derived as in the following table: 
 
Indication for surgery category Calculation 
     Peritonitis -if 5.2 = “Peritonitis” 
     Perforation -if 5.2 = “Perforation” 
     Abdominal infection -if 5.2 = “Abdominal abscess” or “Sepsis”  
or “Intestinal fistula” 
 or “Phlegmon” 
     Intestinal obstruction -if 5.2 = “Intestinal obstruction” 
or “Small bowel obstruction” 
or “Large bowel obstruction”  
or “Volvulus”  
or “Intussusception”  
or “Obstructing incisional hernia” 
     Haemorrhage -if 5.2 = “Haemorrhage” 
     Ischaemia -if 5.2 = “Ischaemia” or “Necrosis” 
     Other -if 5.2 = “Colitis”  
or “Abdominal wound dehiscence”  
or “Abdominal compartment syndrome”  
or “Anastomotic leak”  
or “Other (Please give details)” or “Incarcerated 
hernia” 
or “Pneumoperitoneum” 
or “Pseudo-obstruction” 
or “Internal hernia” 
or “Acidosis” 
or “Iatrogenic injury” 
or “Foreign body” 
Multiple indications -if ≥2 of the above categories are ‘Yes’ 
 
 
 
